Avalo Therapeutics, Inc. (AVTX) Insider Trading
Over the last 3 months, AVTX insiders made 0 open-market buys and 29 sales, a net sale of -$6.3M (SEC Form 4). Over the last 6 months, 67 institutions increased and 33 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
29
Net (3m)
-$6.3M
Insider trades by month Buys Sells
Nov
Nov
Mar
Apr
May
Jun
Context3-month price -22.6%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 4, 2026 | Lind Kevin Robertdirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | KANTOFF AARONdirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Jain Ritadirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Truex Samanthadirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Heffernan Michael Thomasdirector | Grant | 29,500 | $13.96 |
| Jun 4, 2026 | KAPLAN GILLAdirector | Grant | 20,100 | $13.96 |
| Jun 1, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 679 | $16.00 |
| Jun 1, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 679 | $8.04 |
| May 26, 2026 | NEIL GARRY ARTHURdirector, officer: Chief Executive Officer | Grant | 100,200 | — |
| May 26, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Grant | 39,900 | — |
| May 26, 2026 | VARKI PAULofficer: Chief Legal Officer | Grant | 24,300 | — |
| May 26, 2026 | Riley Jenniferofficer: Chief Strategy Officer | Grant | 34,200 | — |
| May 26, 2026 | Doyle Mittieofficer: Chief Medical Officer | Grant | 43,500 | — |
| May 19, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 3,000 | $12.65 |
| May 19, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 3,000 | $18.76 |
| May 11, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Sell | 18,606 | $24.12 |
| May 11, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Option | 18,606 | $9.88 |
| May 7, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Option | 47,000 | $8.04 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 1,679 | $16.00 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 28,650 | $8.04 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 19,015 | $22.41 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 44,944 | $21.20 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 1,000 | $12.65 |
| May 7, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Sell | 9,219 | $21.37 |
| May 7, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Sell | 2,700 | $20.76 |
| May 7, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Sell | 13,834 | $18.55 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 5,000 | $19.65 |
| May 7, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Sell | 12,347 | $19.28 |
| May 7, 2026 | VARKI PAULofficer: Chief Legal Officer | Sell | 22,839 | $21.22 |
| May 7, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 679 | $8.04 |
Source: AVTX SEC Form 4 filings, latest Jun 4, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their AVTX positions over the last 6 months (SEC Form 13F).
Increased
67
New positions
67
Reduced
33
Sold out
29
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 2.9M | May 15, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | New Position | 2.2M | May 15, 2026 |
| CALIGAN PARTNERS LP | Increased | 1.6M | May 15, 2026 |
| BVF INC/IL | Increased | 1.6M | May 15, 2026 |
| AVORO CAPITAL ADVISORS LLC | New Position | 1.4M | May 15, 2026 |
| BVF INC/IL | Increased | 1.4M | Feb 17, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 1.3M | May 14, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 1.2M | May 15, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 1.2M | Feb 13, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 1.2M | Feb 17, 2026 |
| UBS GROUP AG | Increased | 1.1M | May 5, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 1.1M | Feb 13, 2026 |
| LOGOS GLOBAL MANAGEMENT LP | New Position | 1.0M | May 15, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 916K | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | New Position | 916K | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.